Dong Moon Shin, MD, FACP
Professor, Hematology/Oncology & Otolaryngology
Emory University School of Medicine
Frances Kelly Blomeyer Chair in Cancer Research
Emory University School of Medicine
Director, Head and Neck SPORE Program
Winship Cancer Institute of Emory University
Office: Winship Cancer Institute of Emory University
Phone: (404) 778-1947
Fax: (404) 778-5520
Dr. Dong Moon Shin is the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research, Professor of Hematology/Medical Oncology, Professor of Otolaryngology, Director of the Head and Neck Cancer SPORE Program, Georgia Cancer Coalition Distinguished Scholar at the Winship Cancer Institute at Emory University. Dr. Shin has a highly successful scholar and research track record as a head and neck cancer investigator. He is a well established international and national recognized investigator in head and neck cancer research related to biology, biomarkers, chemoprevention, biochemoprevention, nanotherapeutics and molecularly-based innovative new therapy. He has extensive administrative experience as Director of the Clinical and Translational Cancer Prevention Program, Director of the NCI Sponsored Head and Neck Cancer SPORE Program and formerly as the Associate Director of Academic Development at the Winship Cancer Institute of Emory University.
Dr. Shin joined Emory University and the Winship Cancer Institute in 2003, as Professor of Hematology and Oncology and Otolaryngology. He has played a major leadership role in several areas: including the Eastern Cooperative Oncology Group, American Society of Clinical Oncology, American Association of Cancer Research at the national level in addition to Winship Cancer Institute’s Operations Committee and Associate Director of Academic Development at the Winship Cancer Institute, Emory University. Prior to joining Emory University and the Winship Cancer Institute, Dr. Shin graduated from Yonsei University College of Medicine, Seoul, Korea, completed Residency training in Internal Medicine at Cook County Hospital in Chicago, Illinois and trained in Medical Oncology and Research Fellowship at the University of Texas M. D. Anderson Cancer Center and was appointed as tenured professor at the University of Pittsburgh and MD Anderson Medical Center. Dr. Shin has served on the editorial boards of ten cancer related journals and as a study section member on NCI grant review panels. He has been consecutively selected for Best Doctors in America, Top Doctors in Oncology, selected by Atlanta Magazine, and America’s Top Doctors, selected by Castle Connolly Ltd. for many years. He is a board certified physician by the American Board of Internal Medicine (Specialty) and Medical Oncology (Sub-Specialty).
Dr. Shin's scientific accomplishments are highlighted by his success in securing and maintaining highly competitive peer-reviewed funding from the NIH, ACS, FDA and other agencies over the last 20 years.
Dr. Shin's research initially focused on demonstrating the phenomenon of field cancerization and the multistep carcinogenesis process using animal models and analyzing tissue samples from different sites in the aerodigestive tract and premalignant lesions of patients with head and neck cancer. Dr. Shin investigated the chemopreventive efficiency of retinoids in head and neck cancer in preclinical and clinical settings. These compounds, in particular, 13-cRA demonstrated early promise in several prospective double blind, placebo-controlled randomized trials in reversing oral premalignancy and preventing second primary tumors. The long term follow-up of these studies showed only a marginal protective effect, and the use of high doses of 13-cRA was limited by toxicity. To overcome retinoid resistance in the chemopreventive setting, Dr. Shin and his colleagues initiated a combination of 13-cRA, interferon-α, and α-tocopherol in advanced premalignant lesions and in bioadjuvant therapy for advanced head and neck cancer. The results of these studies were highly promising and drew considerable national attention from head and neck cancer researchers. Currently Dr. Shin is continuously focused on biomarker-driven preclinical and clinical chemopreventive studies using synthetic compounds (i.e., EGFR-TKIs, COX inhibitors) and natural compounds, such as green tea polyphenons, luteolin, resveratrol, curcumin and others. Dr. Shin has also focused on anticancer drug delivery using nanotechnology in collaboration with other investigators. Some of the compounds explored will be taken into clinical trials.
Another area of interest includes the study of biomarkers, particularly by using nanotechnology to detect circulating tumor cells in cancer patients. Some of the techniques using gold nanoparticle surface-enhanced raman spectroscopy are highly promising to advance diagnostics and monitor anticancer treatment effects.
Dr. Shin has published over 240 peer reviewed scientific articles in journals such as The New England Journal of Medicine, The Journal of the National Cancer Institute, Cancer Research, and The Journal of Clinical Oncology. Dr. Shin's research is widely cited in thousands of studies and peer reviewed papers.
View clinical trials at Winship Cancer Institute